Search

Your search keyword '"Fuqua, John S."' showing total 175 results
Start Over Author "Fuqua, John S."
175 results on '"Fuqua, John S."'

8. A Retrospective Study of the Use of Gonadotropin-Releasing Hormone Analogs and Testosterone in Transgender Boys: Who, What, When, and for How Long?

Author

Kain, Emily J., Fuqua, John S., and Eugster, Erica A.

Subjects
THERAPEUTIC use of testosterone, TRANS men, ENDOCRINOLOGY, TESTOSTERONE, OUTPATIENT services in hospitals, HEALTH insurance reimbursement, T-test (Statistics), GENDER affirming care, TREATMENT duration, RETROSPECTIVE studies, POSTMENOPAUSE, AGE distribution, MENORRHAGIA, DESCRIPTIVE statistics, PEDIATRICS, GONADOTROPIN releasing hormone, HORMONE therapy, MEDICAL records, ACQUISITION of data, GENDER dysphoria, DRUGS, ADOLESCENCE
Abstract

A retrospective review of gender-affirming hormone therapy was conducted in 101 transgender boys followed in the pediatric endocrine clinic. Eighty-seven percent were postmenarchal at the initial visit. Of the 44% prescribed gonadotropin-releasing hormone analogs (GnRHas), insurance coverage was denied in 34% and an average of 4.5 months elapsed before treatment could be started in the remainder. Patients prescribed GnRHas were younger than those who were not, 13.7±2.1 versus 15.5±2.0 years, p<0.001. Continued menstrual bleeding was reported by patients receiving testosterone alone at doses ranging from 50 to 200 mg every 2 weeks. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. A retrospective review of the use of bicalutamide in transfeminine youth; a single center experience.

Author

Fuqua, John S., Shi, Eda, and Eugster, Erica A.

Subjects
*ESTROGEN replacement therapy, *ANTIANDROGENS, *HEPATOTOXICOLOGY, *PUBERTY, *TREATMENT effectiveness, *RETROSPECTIVE studies, *DESCRIPTIVE statistics, *GENDER affirmation surgery, *BREAST, *TIME
Abstract

Background: Androgen blockers are an essential part of gender affirming care in post-pubertal transfeminine patients. Bicalutamide is a highly potent androgen receptor blocker that is used primarily in adults. We aimed to review our experience with the use of bicalutamide in transgender adolescents who were assigned male at birth. Methods: A retrospective review of medical records of transfeminine patients treated with bicalutamide during an 8-year period was conducted. Results: Forty patients, aged 15.5 ± 1.55 years were identified, of whom 21 (53%) were started on bicalutamide alone and 19 were started concurrently on estrogen. In patients on bicalutamide alone, 90.4% reported breast development at their first follow up visit, which occurred at a median of 7.1 months. Patients were treated for 29.4 ± 18.2 months. No episodes of liver toxicity related to bicalutamide were seen. Conclusions: Although these results are preliminary, bicalutamide appears to be a safe option for androgen blockade in transgender girls. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. OR21-06 Growth Response Of Oral LUM-201 In OraGrowtH210 And OraGrowtH212 Trials In Idiopathic Pediatric Growth Hormone Deficiency (iPGHD): Combined Analysis Interim Analysis Data

Author

Tansey, Michael J, primary, Bowden, Sasigarn Arunchaiya, additional, Dauber, Andrew Nahum, additional, Wikiera, Beata, additional, Pyrzak, Beata, additional, Bossowski, Artur T, additional, Petriczko, Elzbieta, additional, Stawerska, Renata, additional, Moszczynska, Elzbieta, additional, Cassorla, Fernando, additional, Feldt, Matthew M, additional, Lunsford, Alison J, additional, Gottschalk, Michael Everett, additional, Marin, Monica, additional, Nayak, Sunil N, additional, Bhuvana, Sunil, additional, Repaske, David Roy, additional, Soyka, Leslie Ann, additional, Fuqua, John S, additional, Escobar, Oscar, additional, Bowlby, Deborah A, additional, Fechner, Patricia Y, additional, Wiltshire, Esko, additional, Harris, Mark, additional, Wintergerst, Kupper A, additional, Lafferty, Antony Richard A, additional, Miller, Bradley S, additional, Simm, Peter, additional, Bruchey, Aleksandra, additional, Smith, Christopher, additional, Karpf, David B, additional, McKew, John C, additional, and Thorner, Michael O, additional

Published
2023
Full Text
View/download PDF

15. Majority of females with a life-long experience of CAH and parents do not consider females with CAH to be intersex

Author

Braga, Luis H., Donahue, Kelly L., Eugster, Erica A., Fleming, Louise K., Frady, Heather M., Fuqua, John S., Geffner, Mitchell E., Hensel, Devon J., Kim, Mimi S., Kokorowski, Paul, Lekarev, Oksana, Leland, Brian D., Lin-Su, Karen, Meyer-Bahlburg, Heino F.L., Nebesio, Todd D., Poppas, Dix P., Speiser, Phyllis W., Szymanski, Konrad M., Rink, Richard C., Routh, Jonathan C., Whittam, Benjamin, Talib, Rashida, and Yasuda, Patrice M.

Published
2021
Full Text
View/download PDF

20. Sexual Differentiation

Author

Hannon, Tamara S., Fuqua, John S., Conn, P. Michael, editor, Eugster, Erica A., editor, and Pescovitz, Ora Hirsch, editor

Published
2002
Full Text
View/download PDF

22. Current State of Pediatric Reference Intervals and the Importance of Correctly Describing the Biochemistry of Child Development

Author

Lyle, Alicia N., primary, Pokuah, Fidelia, additional, Dietzen, Dennis J., additional, Wong, Edward C. C., additional, Pyle-Eilola, Amy L., additional, Fuqua, John S., additional, Woodworth, Alison, additional, Jones, Patricia M., additional, Akinbami, Lara J., additional, Garibaldi, Luigi R., additional, and Vesper, Hubert W., additional

Published
2022
Full Text
View/download PDF

29. Majority of females with a life-long experience of CAH and parents do not consider females with CAH to be intersex

Author

Szymanski, Konrad M., primary, Rink, Richard C., additional, Whittam, Benjamin, additional, Hensel, Devon J., additional, Braga, Luis H., additional, Donahue, Kelly L., additional, Eugster, Erica A., additional, Fleming, Louise K., additional, Frady, Heather M., additional, Fuqua, John S., additional, Geffner, Mitchell E., additional, Kim, Mimi S., additional, Kokorowski, Paul, additional, Lekarev, Oksana, additional, Leland, Brian D., additional, Lin-Su, Karen, additional, Meyer-Bahlburg, Heino F.L., additional, Nebesio, Todd D., additional, Poppas, Dix P., additional, Speiser, Phyllis W., additional, Szymanski, Konrad M., additional, Routh, Jonathan C., additional, Talib, Rashida, additional, and Yasuda, Patrice M., additional

Published
2021
Full Text
View/download PDF

34. Determination of trace isoflavone phytoestrogens in biological materials by capillary electrochromatography

Author

Starkey, Jason A., Mechref, Yehia, Byun, Chang Kyu, Steinmetz, Rosemary, Fuqua, John S., Pescovitz, Ora H., and Novotny, Milos V.

Subjects
Chromatography -- Evaluation, Chromatography -- Methods, Chromatographic analysis, Chemistry
Abstract

Capillary electrochromatography using a specialty monolithic matrix was utilized in developing a rapid and highly efficient separation of isoflavones in biological materials. Without a preconcentration technique, it is relatively easy to reach ppm-ppb concentrations of these compounds in soy-based foods and verify them structurally using a photodiode array detector. With on-column preconcentration, we were able to measure low-ppb levels in human serum. Using blood samples from human volunteers, whose diet was supplemented by a soy-based product, the method has been validated for high-throughput screening of isoflavones in clinical studies.

Published
2002

43. Use of Gonadotropin-Releasing Hormone Analogs in Children:Update by an International Consortium

Author

Bangalore Krishna, Kanthi, Fuqua, John S, Rogol, Alan D, Klein, Karen O, Popovic, Jadranka, Houk, Christopher P, Charmandari, Evangelia, Lee, Peter A, Freire, A V, Ropelato, M G, Yazid Jalaludin, M, Mbogo, J, Kanaka-Gantenbein, C, Luo, X, Eugster, E A, Klein, K O, Vogiatzi, M G, Reifschneider, K, Bamba, V, Garcia Rudaz, C, Kaplowitz, P, Backeljauw, P, Allen, D B, Palmert, M R, Harrington, J, Guerra-Junior, G, Stanley, T, Torres Tamayo, M, Miranda Lora, A L, Bajpai, A, Silverman, L A, Miller, B S, Dayal, A, Horikawa, R, Oberfield, S, Rogol, A D, Tajima, T, Popovic, J, Witchel, S F, Rosenthal, S M, Finlayson, C, Hannema, S E, Castilla-Peon, M F, Mericq, V, and Medina Bravo, P G

Subjects
Male, medicine.medical_specialty, Future studies, Adolescent, Pediatric endocrinology, Endocrinology, Diabetes and Metabolism, Puberty, Precocious, 030209 endocrinology & metabolism, Gonadotropin-releasing hormone, Gonadotropin-Releasing Hormone, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Transgender, medicine, Precocious puberty, Humans, Adverse effect, Child, 030219 obstetrics & reproductive medicine, business.industry, medicine.disease, Family medicine, Pediatrics, Perinatology and Child Health, Narrative review, Female, Outcome data, business
Abstract

This update, written by authors designated by multiple pediatric endocrinology societies (see List of Participating Societies) from around the globe, concisely addresses topics related to changes in GnRHa usage in children and adolescents over the last decade. Topics related to the use of GnRHa in precocious puberty include diagnostic criteria, globally available formulations, considerations of benefit of treatment, monitoring of therapy, adverse events, and long-term outcome data. Additional sections review use in transgender individuals and other pediatric endocrine related conditions. Although there have been many significant changes in GnRHa usage, there is a definite paucity of evidence-based publications to support them. Therefore, this paper is explicitly not intended to evaluate what is recommended in terms of the best use of GnRHa, based on evidence and expert opinion, but rather to describe how these drugs are used, irrespective of any qualitative evaluation. Thus, this paper should be considered a narrative review on GnRHa utilization in precocious puberty and other clinical situations. These changes are reviewed not only to point out deficiencies in the literature but also to stimulate future studies and publications in this area.

Published
2019
Full Text
View/download PDF

47. Short stature and the effect of human growth hormone: Guidelines for the care of people with spina bifida.

Author

O'Neil, Joseph, Fuqua, John S., Brei, Timothy, Castillo, Heidi, and Castillo, Jonathan

Subjects
*MEDICAL care, *MEDICAL protocols, *PATIENTS, *SPINA bifida, *HUMAN growth hormone
Abstract

It is estimated that a significant percentage of individuals with spina bifida (SB) are shorter than their age-matched typical peers. Parents of children with spina bifida may ask if human growth hormone is appropriate for their child. This article discusses short stature and the use of human growth hormone among children with SB. This guideline was developed for SB Healthcare Guidelines from the 2018 Spina Bifida Association's Fourth Edition of the Guidelines for the Care of People with Spina Bifida. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results